News Botanix Pharmaceuticals Limited

Equities

BOT

AU000000BOT2

Delayed Australian S.E. Other stock markets 12:39:57 2024-06-11 am EDT			5-day change	1st Jan Change
0.28 ^AUD	+1.82%		-1.75%	+47.37%

May. 21	Evans & Partners Starts Botanix Pharmaceuticals at Speculative Buy With AU$0.55 Price Target	MT
May. 13	Euroz Hartleys Adjusts Botanix Pharmaceutical’s Price Target to AU$0.33 From AU$0.30, Keeps at Speculative Buy	MT

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Evans & Partners Starts Botanix Pharmaceuticals at Speculative Buy With AU$0.55 Price Target	May. 21	MT
Euroz Hartleys Adjusts Botanix Pharmaceutical’s Price Target to AU$0.33 From AU$0.30, Keeps at Speculative Buy	May. 13	MT
Botanix Pharmaceuticals Limited(ASX:BOT) added to S&P/ASX All Ordinaries Index	Mar. 17	CI
Botanix Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 27	CI
US FDA Accepts Resubmission of Botanix Pharmaceuticals' Topical Medication	Jan. 21	MT
Botanix Pharmaceuticals Completes US FDA Resubmission for Topical Medication; Shares Gain 3%	Dec. 20	MT
Botanix Pharmaceuticals Completes Human Factors Validation Study for Topical Medication; Shares Rise 3%	Dec. 13	MT
Botanix Pharmaceuticals Secures US FDA Feedback for Topical Medication	Dec. 04	MT
Botanix Pharmaceuticals Limited Receives Feedback from FDA	Dec. 03	CI
Botanix Pharmaceuticals Completes Nearly AU$14 Million Institutional Placement	Dec. 01	MT
Botanix Pharmaceuticals to Raise AU$13.5 Million in Placement; Shares Fall 3%	Nov. 26	MT
Acne Vulgaris Pipeline\| Clinical Trials, Key Companies - Novan, Bausch Health AOBiome, Ascletis Pharmaceuticals, AnaptysBio, Botanix Pharmaceuticals	Nov. 07	AQ
Moderate to Severe Inflammatory Acne Vulgaris Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	23-10-27	AQ
Botanix Pharmaceuticals Signs Telehealth Deal for Dermatological Product	23-10-23	MT
Botanix Pharmaceuticals Secures Conditional US FDA Clearance for Use of 'Sofra' Trade Name	23-10-16	MT
Botanix Pharmaceuticals Limited(ASX:BOT) added to S&P/ASX Emerging Companies Index	23-09-18	CI
Botanix Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-30	CI
Botanix Pharmaceuticals Promotes COO to CEO	23-08-25	MT
Botanix Pharmaceuticals Limited Appoints Howie Mckibbon as Chief Executive Officer	23-08-24	CI
Fresh Tracks Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update	23-08-14	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Botanix Pharmaceuticals Limited

Equities

BOT

AU000000BOT2

Summary

Filters